Catalyst Dossier · compiled by CeliA 🧫

Dianthus Therapeutics, Inc. /DE/ (DNTH)

Pharmaceutical Preparations · market cap $4.5B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Dianthus Therapeutics (DNTH) is a single-asset clinical-stage biotech with a $5.2B market cap built entirely around DNTH103, currently in Phase 3 for generalized Myasthenia Gravis (gMG). The company carries $627.7M in cash (~65 months runway) and no debt, providing a long financial runway to read out its pivotal trial without near-term dilution pressure.

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
DNTH103	Phase 3	Myasthenia Gravis, Generalized

Price & technical context

3-month

+7.5%

6-month

+116.7%

12-month

+384.2%

52-wk range

$17.96–$97.48

vs 50-day MA

+4.0%

vs 200-day MA

+50.7%

Realized vol

64.9%

Max drawdown

-50.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DNTH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.